Abstract: Insulin resistance plays a key role in the pathogenesis of polycystic ovary syndrome. Therefore thiazolidinediones and metformin, which have been used in clinical therapy to treat patients with polycystic ovary syndrome, can ameliorate insulin resistance,resulting in the improvement of some metabolic abnormalities, hyperandrogenic symptoms, menses, ovulation and pregnancy rates. Metformin therapy throughout pregnancy may reduce in pregnancy complications, such as miscarriage rate, gestational hypertension and gestational diabetes.

Key words: polycystic ovary syndrome, insulin resistance, metformin, thiazolidinediones